Sandoz, a Novartis (NVS) unit, said Monday that the US Supreme Court has denied its petition to review the Federal Circuit's July 2020 decision concerning the Sandoz biosimilar Erelzi or etanercept-szzs for reference medicine Enbrel or etanercept. The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen's patents.
Sandoz said it is disappointed the Supreme Court decided not to review its case. The decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029. However, the company remains committed to providing important treatment options for patients affected by these diseases.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.